Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2012

Carter RL, Kang L, Darcy KM, Kauderer J, Liao S-, Rodgers WH, et al. A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study. Cancer Causes Control. 2012;23(12):2013-21.

Métais J-, Winkler T, Geyer JT, Calado RT, Aplan PD, Eckhaus MA, et al. BCL2A1a over-expression in murine hematopoietic stem and progenitor cells decreases apoptosis and results in hematopoietic transformation. PLoS One. 2012;7(10):e48267.

Cooper N, Stasi R, Cunningham-Rundles S, Cesarman E, McFarland JG, Bussel JB. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. Br J Haematol. 2012;158(4):539-47.

Berman DM, Bosenberg MW, Orwant RL, Thurberg BL, Draetta GF, Fletcher CD, et al. Investigative pathology: leading the post-genomic revolution. Lab Invest. 2012;92(1):4-8.

Minkis K, Aksentijevich I, Goldbach-Mansky R, Magro C, Scott R, Davis JG, et al. Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Arch Dermatol. 2012;148(6):747-52.

Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JY, Chen CX, et al. Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proc Natl Acad Sci U S A. 2012;109(17):6686-91.

Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W, et al. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2012;11(3):670-9.

Arinsburg SA, Skerrett DL, Friedman MT, Cushing MM. A survey to assess transfusion medicine education needs for clinicians. Transfus Med. 2012;22(1):44-9; quiz 49-51.

Sawai CM, Freund J, Oh P, Ndiaye-Lobry D, Bretz JC, Strikoudis A, et al. Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell. 2012;22(4):452-65.

Veerappan A, Reid AC, O'Connor N, Mora R, Brazin JA, Estephan R, et al. Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model. Am J Physiol Renal Physiol. 2012;302(1):F192-204.